×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TEVA – teva pharmaceutical industries limited american depositary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TEVA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/24
04:30 pm
teva
Teva to Present at the Upcoming Investor Conferences in March
Low
Report
Teva to Present at the Upcoming Investor Conferences in March
2/20
07:12 pm
teva
Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Teva Pharmaceutical Industries (TEVA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
2/20
03:37 pm
teva
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Low
Report
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
2/20
02:43 pm
teva
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Low
Report
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
2/19
04:02 pm
teva
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals [Yahoo! Finance]
Low
Report
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals [Yahoo! Finance]
2/19
11:11 am
teva
Corcept falls as appeals court sides with Teva in Korlym patent dispute [Seeking Alpha]
Low
Report
Corcept falls as appeals court sides with Teva in Korlym patent dispute [Seeking Alpha]
2/18
10:42 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
2/17
06:00 am
teva
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Low
Report
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Date
Time
Symbol
Company Name
Action
%Chg
1/28/2026
07:00 am
TEVA
teva pharmaceutical industries limited american depositary shares
BEAT
Report
4.4%
teva pharmaceutical industries limited american depositary shares
11/5/2025
07:00 am
TEVA
teva pharmaceutical industries limited american depositary shares
BEAT
Report
9.9%
teva pharmaceutical industries limited american depositary shares
7/30/2025
07:00 am
TEVA
teva pharmaceutical industries limited american depositary shares
BEAT
Report
0.4%
teva pharmaceutical industries limited american depositary shares
5/7/2025
07:00 am
TEVA
teva pharmaceutical industries limited american depositary shares
BEAT
Report
5.3%
teva pharmaceutical industries limited american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/23
04:17 pm
teva
Form 3 TEVA PHARMACEUTICAL INDU For: Feb 11 Filed by: Savage Brian
Low
Report
Form 3 TEVA PHARMACEUTICAL INDU For: Feb 11 Filed by: Savage Brian
2/18
04:01 pm
teva
Form 4 TEVA PHARMACEUTICAL INDU For: Feb 15 Filed by: Francis Richard D
Low
Report
Form 4 TEVA PHARMACEUTICAL INDU For: Feb 15 Filed by: Francis Richard D
2/18
06:29 am
teva
Form 144/A TEVA PHARMACEUTICAL INDU Filed by: Francis Richard D
Low
Report
Form 144/A TEVA PHARMACEUTICAL INDU Filed by: Francis Richard D
2/18
06:12 am
teva
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Francis Richard D
Low
Report
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Francis Richard D
2/17
11:06 am
teva
Form SCHEDULE 13G TEVA PHARMACEUTICAL INDU Filed by: Migdal Insurance & Financial Holdings Ltd.
Low
Report
Form SCHEDULE 13G TEVA PHARMACEUTICAL INDU Filed by: Migdal Insurance & Financial Holdings Ltd.
2/9
06:04 am
teva
Form SCHEDULE 13G/A TEVA PHARMACEUTICAL INDU Filed by: Harel Insurance Investments & Financial Services Ltd.
Low
Report
Form SCHEDULE 13G/A TEVA PHARMACEUTICAL INDU Filed by: Harel Insurance Investments & Financial Services Ltd.
2/3
08:59 am
teva
Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31
Low
Report
Form 10-K TEVA PHARMACEUTICAL INDU For: Dec 31
1/29
04:08 pm
teva
Form 4 TEVA PHARMACEUTICAL INDU For: Jan 27 Filed by: Kalif Eliyahu Sharon
Low
Report
Form 4 TEVA PHARMACEUTICAL INDU For: Jan 27 Filed by: Kalif Eliyahu Sharon
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/18
Shortage of critical children’s cancer drug causes concerns nationwide [MSNBC.com]
16.9%
8/7 Dow Takes a Sharp Dive as Treasury Yields Tumble [TheStreet.com] 13.9%
2/12 New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion 10.7%
11/7 Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 10.5%
10/16 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was upgraded by analysts at Gabelli from a "hold" rating to a "buy" rating. 10.4%
1/13 Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 38th Annual JP Morgan Healthcare Conference (Transcript) [Seeking Alpha] 9.7%
2/3 Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan 7.7%
9/6 Purdue Pharma in talks to settle DOJ opioid probes - WSJ [Seeking Alpha] 7.2%
6/24 UPDATE 2-Oklahoma judge approves Teva's $85 million opioid settlement [Reuters (UK)] 7.0%
11/26 U.S. prosecutors open criminal probe of opioid makers, distributors [Reuters (UK)] 6.7%
8/7 Dow Takes a Sharp Dive as Treasury Yields Tumble [TheStreet.com] 13.9%
2/12 New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion 10.7%
11/7 Form 10-Q TEVA PHARMACEUTICAL INDU For: Sep 30 10.5%
10/16 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was upgraded by analysts at Gabelli from a "hold" rating to a "buy" rating. 10.4%
1/13 Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 38th Annual JP Morgan Healthcare Conference (Transcript) [Seeking Alpha] 9.7%
2/3 Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan 7.7%
9/6 Purdue Pharma in talks to settle DOJ opioid probes - WSJ [Seeking Alpha] 7.2%
6/24 UPDATE 2-Oklahoma judge approves Teva's $85 million opioid settlement [Reuters (UK)] 7.0%
11/26 U.S. prosecutors open criminal probe of opioid makers, distributors [Reuters (UK)] 6.7%
TOP News Decliners
5/11
U.S. states sue Teva, 19 other drug companies in price-fixing complaint [Reuters (UK)]
-14.7%
5/28 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. -13.8%
3/12 Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®? (fremanezumab) -13.5%
8/6 Earnings Outlook: Teva Pharmaceuticals reports earnings on Wednesday. Here’s what to expect [MarketWatch] -11.2%
3/19 Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide -10.2%
11/25 Form 8-K TEVA PHARMACEUTICAL INDU For: Nov 25 -8.0%
5/30 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was downgraded by analysts at Bank of America Corp from a "buy" rating to an "underperform" rating. -6.9%
4/21 QuestCap Appoints Douglas Sommerville as President of MedQuest Investment Division [Canadian Business Journal (Canada)] -6.9%
10/7 Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019 -6.4%
11/6 Form 4 TEVA PHARMACEUTICAL INDU For: Nov 05 Filed by: McClellan Michael James -6.1%
5/28 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. -13.8%
3/12 Positive Recommendation by NICE for first anti-CGRP migraine therapy: AJOVY®? (fremanezumab) -13.5%
8/6 Earnings Outlook: Teva Pharmaceuticals reports earnings on Wednesday. Here’s what to expect [MarketWatch] -11.2%
3/19 Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide -10.2%
11/25 Form 8-K TEVA PHARMACEUTICAL INDU For: Nov 25 -8.0%
5/30 Teva Pharmaceutical Industries Ltd (NYSE: TEVA) was downgraded by analysts at Bank of America Corp from a "buy" rating to an "underperform" rating. -6.9%
4/21 QuestCap Appoints Douglas Sommerville as President of MedQuest Investment Division [Canadian Business Journal (Canada)] -6.9%
10/7 Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019 -6.4%
11/6 Form 4 TEVA PHARMACEUTICAL INDU For: Nov 05 Filed by: McClellan Michael James -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: